Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on January 29, 2016, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

**Particulars**

1. Class of shares acquired: Common stock of the Company
2. Total number of shares acquired: 17,000,000 shares
3. Aggregate amount of acquisition cost: 27,455,199,463 yen
4. Period of acquisition: From February 1, 2016 to March 1, 2016
5. Method of acquisition: Purchased on the Tokyo Stock Exchange

(Reference)

Details of the resolution at the meeting of the Board of Directors (announced on January 29, 2016)

- Class of shares to be acquired: Common stock of the Company
- Total number of shares to be acquired: Up to 17 million shares
  (The percentage compared to the total number of shares outstanding: 0.79%)
- Aggregate amount of acquisition cost: Up to 30 billion yen
- Period of acquisition: From February 1, 2016 to March 11, 2016

For inquiries or additional information

<table>
<thead>
<tr>
<th>For inquiries or additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astellas Pharma Inc.</td>
</tr>
<tr>
<td>Corporate Communications</td>
</tr>
<tr>
<td>TEL: +81-3-3244-3201, FAX:+81-3-5201-7473</td>
</tr>
<tr>
<td><a href="http://www.astellas.com/en">http://www.astellas.com/en</a></td>
</tr>
</tbody>
</table>